CRSP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
10.2M
+598.3%
1.5M
+68.8%
864.0K
-2.8%
889.0K
-0.3%
892.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
10.2M
+598.3%
1.5M
+68.8%
864.0K
-2.8%
889.0K
-0.3%
892.0K
Operating Expenses
127.5M
-3.2%
131.7M
-15.4%
155.6M
+17.1%
132.9M
-42.3%
230.2M
R&D
69.6M
+1.5%
68.6M
-17.9%
83.5M
+41.8%
58.9M
-64.5%
166.1M
SG&A
17.6M
+2.2%
17.2M
-6.6%
18.4M
+8.7%
16.9M
-10.5%
18.9M
Operating Income
-117269000
+10.0%
-130248000
+15.8%
-154764000
-17.2%
-132059000
+42.4%
-229324000
EBITDA
-112989000
+10.3%
-125929000
+15.5%
-149103000
-16.8%
-127626000
+43.2%
-224675000
Net Income
-91154000
+25.8%
-122931000
+5.9%
-130613000
-22.7%
-106441000
+49.0%
-208549000
EPS (Basic)
$-0.94
+26.6%
$-1.28
+6.6%
$-1.37
-17.1%
$-1.17
+51.3%
$-2.40
EPS (Diluted)
$-0.94
+26.6%
$-1.28
+6.6%
$-1.37
-17.1%
$-1.17
+51.3%
$-2.40
Shares (Diluted)
96.5M
+0.5%
96.1M
+0.7%
95.4M
+4.5%
91.3M
+4.9%
87.1M
CRISPR Therapeutics (CRSP) โ€” Financials